All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit Know AML.
The aml Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the aml Hub cannot guarantee the accuracy of translated content. The aml and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The AML Hub is an independent medical education platform, sponsored by Daiichi Sankyo, Johnson & Johnson, and Syndax, and has been supported through an educational grant from the Hippocrate Conference Institute, an association of the Servier Group. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View aml content recommended for you
Tapan M. KadiaAt the 2019 ASCO Annual Meeting in Chicago, US, Tapan M. Kadia from MD Anderson Cancer Center, Houston, US, discusses the current challenges facing AML treatment.
Dr. Kadia discusses the significant improvement in many of the current therapies, with the discovery and recent approval of drugs such as venetoclax and IDH1 and IDH2 inhibitors as well as new FLT3 inhibitors, however, there are several challenges that still remain. Dr. Kadia explains that some of the biggest challenges that still remain are the ones that occur when patients have secondary AML, prior myeloblastic syndrome or aplastic anemia, which have then transformed into acute myeloid leukemia.
What are the current challenges facing AML treatment?